Evidence map›Paper›PMID 29193288›Full record

ArticleMagnetic resonance in medicine2018

Characterization of tumor vascular permeability using natural dextrans and CEST MRI.

Yuguo Li, Yuan Qiao, Hanwei Chen, Renyuan Bai, Verena Staedtke, Zheng Han, Jiadi Xu, Kannie W Y Chan, Nirbhay Yadav, Jeff W M Bulte and 3 more

Abstract read
In one paragraph

Article in Magnetic resonance in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. CEST MRI trackable nanoparticle drug delivery systems.Biomedical materials (Bristol, England) · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Yuguo LiF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Yuan QiaoLudwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Hanwei ChenDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Renyuan BaiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Verena StaedtkeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zheng HanF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Jiadi XuF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Kannie W Y ChanF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Nirbhay YadavF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Jeff W M BulteF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Shibin ZhouLudwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Peter C M van ZijlF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Guanshu LiuF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Johns Hopkins Medicine · USJohns Hopkins University · USKennedy Krieger Institute · USSidney Kimmel Comprehensive Cancer Center · USCity University of Hong Kong · HK

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Development and Translation of D-glucose as a Diagnostic Agent for MRI of CancerR01EB019934 · NIBIB · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI VAN ZIJL, PETER CM · 2015 to 2019
$5.7M
Novel Approaches for CEST Labeling, Detection, Quantification and TranslationR01EB015032 · NIBIB · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI VAN ZIJL, PETER CM · 2011 to 2019
$3.9M
Noninvasive prediction of tumor response to gemcitabine using MRIR01CA211087 · NCI · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LIU, GUANSHU · 2017 to 2020
$1.5M
DIACEST Islet Cell Capsules for Immunoprotection, MR Detection, and pH SensingR01EB012590 · NIBIB · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI MCMAHON, MICHAEL T · 2010 to 2013
$1.3M
Monitoring Prodrug Delivery in Suicide Gene Therapy Using CEST MRIR21EB015609 · NIBIB · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LIU, GUANSHU · 2012 to 2013
$433k
CEST MRI assessment of tumor vascular permeability using non-labeled dextransR21CA215860 · NCI · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LIU, GUANSHU · 2017 to 2018
$352k
Optimization of CEST MRI for detection of bacteriaR03EB021573 · NIBIB · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LIU, GUANSHU · 2016 to 2017
$162k
NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA211087NCI NIH HHS R21 CA215860NIBIB NIH HHS R01 EB012590NIBIB NIH HHS R01 EB015032NIBIB NIH HHS R01 EB019934NIBIB NIH HHS R03 EB021573NIBIB NIH HHS R21 EB015609
6 · The paper itself

Abstract

purposeTo investigate the use of natural dextrans as nano-sized chemical exchange saturation transfer (CEST) MRI probes for characterizing size-dependent tumor vascular permeability.

methodsDextrans of different molecular weight (10, 70, 150, and 2000 kD) were characterized for their CEST contrast. Mice (N = 5) bearing CT26 subcutaneous colon tumors were injected intravenously with 10 kD (D10, 6 nm) and 70 kD (D70, 12 nm) dextran at a dose of 375 mg/kg. The CEST-MRI signal in the tumors was assessed before and approximately 40 min after each injection using a dynamic CEST imaging scheme.

resultsAll dextrans of different molecular weights have a strong CEST signal with an apparent maximum of approximately 0.9 ppm. The detectability and effects of pH and saturation conditions (B

conclusionsAs a first application, we used 10- and 70-kD dextrans to visualize the spatially variable, size-dependent permeability in the tumor, indicating that nano-sized dextrans can be used for characterizing tumor vascular permeability with dexCEST MRI and, potentially, for developing dextran-based theranostic drug delivery systems. Magn Reson Med 79:1001-1009, 2018. © 2017 International Society for Magnetic Resonance in Medicine.

Indexed as

NeoplasmsAlgorithmsAnimalsCapillary PermeabilityCell Line, TumorDextransFemaleMagnetic Resonance ImagingMiceMice, Inbred BALB CDextranscancerCESTdextranMRIpermeability

Identifiers

PMID29193288
PMCPMC5772994
OpenAlexW2770564273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.